Latest & greatest articles for prostate cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer

41. Evaluating the potential benefit of reduced planning target volume margins for low and intermediate risk patients with prostate cancer using real-time electromagnetic tracking

Evaluating the potential benefit of reduced planning target volume margins for low and intermediate risk patients with prostate cancer using real-time electromagnetic tracking 30370364 2018 11 14 2452-1094 3 4 2018 Oct-Dec Advances in radiation oncology Adv Radiat Oncol Evaluating the potential benefit of reduced planning target volume margins for low and intermediate risk patients with prostate cancer using real-time electromagnetic tracking. 630-638 10.1016/j.adro.2018.06.004 The aim (...) of this study is to quantify and describe the feasibility, clinical outcomes, and patient-reported outcomes of reduced planning target volume (PTV) margins for prostate cancer treatment using real-time, continuous, intrafraction monitoring with implanted radiation frequency transponder beacons. For this prospective, nonrandomized trial, the Calypso localization system was used for intrafraction target localization in 31 patients with a PTV margin reduced to 2 mm in all directions. A total of 1333 fractions

Advances in radiation oncology2018 Full Text: Link to full Text with Trip Pro

42. Contemporary Radiation Treatment of Prostate Cancer in Africa: A Ghanaian Experience

Contemporary Radiation Treatment of Prostate Cancer in Africa: A Ghanaian Experience 30085846 2018 12 07 2378-9506 4 2018 Jul Journal of global oncology J Glob Oncol Contemporary Radiation Treatment of Prostate Cancer in Africa: A Ghanaian Experience. 1-13 10.1200/JGO.17.00234 Purpose Data on prostate cancer (PCa) treatment in Africa remains under-reported. We present a review of the management of PCa at the cancer center of the largest tertiary referral facility in Ghana, with emphasis (...) 25220842 Brachytherapy. 2012 Jan-Feb;11(1):6-19 22265434 Prostate Cancer. 2013;2013:560857 23476788 Lancet. 2002 Jul 13;360(9327):103-6 12126818 J Urol. 2004 Apr;171(4):1393-401 15017184 Lancet Oncol. 2014 Apr;15(4):464-73 24581940 Afr J Med Med Sci. 2009 Jun;38 Suppl 2:5-13 20229733 Brachytherapy. 2007 Oct-Dec;6(4):267-71 17959423 Glob J Health Sci. 2014 Oct 27;7(1):296-314 25560361 Health Policy Plan. 1998 Jun;13(2):181-8 10180407 J Urol. 2014 Sep;192(3):730-5 24747091 Ann Intern Med. 2017 Oct 3;167

Journal of global oncology2018 Full Text: Link to full Text with Trip Pro

43. Systems pharmacology using mass spectrometry identifies critical response nodes in prostate cancer

Systems pharmacology using mass spectrometry identifies critical response nodes in prostate cancer 29977602 2018 12 21 2056-7189 4 2018 NPJ systems biology and applications NPJ Syst Biol Appl Systems pharmacology using mass spectrometry identifies critical response nodes in prostate cancer. 26 10.1038/s41540-018-0064-1 In the United States alone one in five newly diagnosed cancers in men are prostate carcinomas (PCa). Androgen receptor (AR) status and the PI3K-AKT-mTOR signal transduction (...) Rev Urol. 2008 Spring;10(2):111-9 18660852 Cancer Res. 1995 Jan 15;55(2):342-7 7529134 Mol Cell Endocrinol. 2012 Mar 5;350(1):107-17 22155408 Nucleic Acids Res. 2016 Jan 4;44(D1):D481-7 26656494 Cancer Res. 2012 Dec 1;72(23):6142-52 22971343 Cell. 2012 Mar 16;148(6):1089-98 22424221 Nat Genet. 1995 Apr;9(4):401-6 7795646 Cancer Res. 2003 Jul 1;63(13):3799-804 12839976 Proteomics. 2015 Sep;15(18):3193-208 26097198 Prostate Cancer Prostatic Dis. 2014 Dec;17(4):310-4 25156059 Genes Chromosomes Cancer

NPJ systems biology and applications2018 Full Text: Link to full Text with Trip Pro

44. Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921

Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921 29624463 2018 06 15 1527-7755 36 15 2018 May 20 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After (...) Radical Prostatectomy: SWOG S9921. 1498-1504 10.1200/JCO.2017.76.4126 Purpose Patients with high-risk prostate cancer after radical prostatectomy are at risk for death. Adjuvant androgen-deprivation therapy (ADT) may reduce this risk. We hypothesized that the addition of mitoxantrone and prednisone (MP) to adjuvant ADT could reduce mortality compared with adjuvant ADT alone. Methods Eligible patients had cT1-3N0 prostate cancer with one or more high-risk factors after radical prostatectomy (Gleason

EvidenceUpdates2018

45. Prostate cancer

Prostate cancer Autosynthesis - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing

Trip Evidence Maps2018

46. Efferocytosis and prostate cancer skeletal metastasis: implications for intervention

Efferocytosis and prostate cancer skeletal metastasis: implications for intervention 30035182 2018 11 14 2331-4737 5 5-6 2018 May Oncoscience Oncoscience Efferocytosis and prostate cancer skeletal metastasis: implications for intervention. 174-176 10.18632/oncoscience.440 Roca Hernan H Department of Periodontics and Oral Medicine, University of Michigan, School of Dentistry, Ann Arbor, MI 48109-1078, USA. McCauley Laurie K LK Department of Periodontics and Oral Medicine, University of Michigan (...) , School of Dentistry, Ann Arbor, MI 48109-1078, USA. eng P01 CA093900 CA NCI NIH HHS United States R01 DK053904 DK NIDDK NIH HHS United States Editorial 2018 06 29 United States Oncoscience 101636666 2331-4737 efferocytosis inflammation macrophage prostate cancer skeletal metastasis CONFLICTS OF INTEREST The authors declare no conflicts of interest. 2018 05 02 2018 05 18 2018 7 24 6 0 2018 7 24 6 0 2018 7 24 6 1 epublish 30035182 10.18632/oncoscience.440 440 PMC6049312 Cancer Cell. 2016 Apr 11;29(4

Oncoscience2018 Full Text: Link to full Text with Trip Pro

47. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. BACKGROUND: Men with nonmetastatic, castration-resistant prostate cancer and a rapidly rising prostate-specific antigen (PSA) level are at high risk for metastasis. We hypothesized that enzalutamide, which prolongs overall survival among patients with metastatic, castration-resistant prostate cancer, would delay metastasis in men with nonmetastatic, castration-resistant prostate cancer and a rapidly rising PSA level (...) . METHODS: In this double-blind, phase 3 trial, we randomly assigned, in a 2:1 ratio, men with nonmetastatic, castration-resistant prostate cancer and a PSA doubling time of 10 months or less who were continuing androgen-deprivation therapy to receive enzalutamide (at a dose of 160 mg) or placebo once daily. The primary end point was metastasis-free survival (defined as the time from randomization to radiographic progression or as the time to death without radiographic progression). RESULTS: A total

NEJM2018

48. Salvage reirradiation for local failure of prostate cancer after curative radiation therapy: Association of rectal toxicity with dose distribution and normal-tissue complication probability models

Salvage reirradiation for local failure of prostate cancer after curative radiation therapy: Association of rectal toxicity with dose distribution and normal-tissue complication probability models 30370369 2018 11 14 2452-1094 3 4 2018 Oct-Dec Advances in radiation oncology Adv Radiat Oncol Salvage reirradiation for local failure of prostate cancer after curative radiation therapy: Association of rectal toxicity with dose distribution and normal-tissue complication probability models. 673-681 (...) 10.1016/j.adro.2018.06.001 This study aimed to assess the impact of radiation dose on rectal toxicity after salvage external beam radiation therapy (EBRT) with or without a brachytherapy boost for exclusive local failures after the primary EBRT for prostate cancer. Fourteen patients with no severe residual late toxicity after primary EBRT ± brachytherapy were reirradiated after a median time interval of 6.1 years. The median normalized total dose in 2 Gy fractions (NTD 2Gy , α/β ratio = 1.5 Gy

Advances in radiation oncology2018 Full Text: Link to full Text with Trip Pro

49. Risk factors for late bowel and bladder toxicities in NRG Oncology prostate cancer trials of high-risk patients: A meta-analysis of physician-rated toxicities

Risk factors for late bowel and bladder toxicities in NRG Oncology prostate cancer trials of high-risk patients: A meta-analysis of physician-rated toxicities 30202809 2018 11 14 2452-1094 3 3 2018 Jul-Sep Advances in radiation oncology Adv Radiat Oncol Risk factors for late bowel and bladder toxicities in NRG Oncology prostate cancer trials of high-risk patients: A meta-analysis of physician-rated toxicities. 405-411 10.1016/j.adro.2018.04.010 A meta-analysis of sociodemographic variables (...) and their association with late (>180 days from start of radiation therapy[RT]) bowel, bladder, and clustered bowel and bladder toxicities was conducted in patients with high-risk (clinical stages T2c-T4b or Gleason score 8-10 or prostate-specific antigen level >20) prostate cancer. Three NRG trials (RTOG 9202, RTOG 9413, and RTOG 9406) that accrued from 1992 to 2000 were used. Late toxicities were measured with the Radiation Therapy Oncology Group Late Radiation Morbidity Scale. After controlling for study, age

Advances in radiation oncology2018 Full Text: Link to full Text with Trip Pro

51. Optimizing Anticancer Therapy in Metastatic Non-castrate Prostate Cancer

Optimizing Anticancer Therapy in Metastatic Non-castrate Prostate Cancer ');//--> ');//--> Search in: Menu COOKIES REQUIRED In order to access this website, please configure your browser to support cookies. ASCO Family of Sites Journals Publications Education Other Sites 2318 Mill Road, Suite 800, Alexandria, VA 22314 © 2018 American Society of Clinical Oncology |

American Society of Clinical Oncology Guidelines2018

52. Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline

Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline 29608397 2018 05 16 1527-7755 36 15 2018 May 20 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline. 1521-1539 10.1200/JCO.2018.78.0619 Purpose This clinical (...) practice guideline addresses abiraterone or docetaxel with androgen-deprivation therapy (ADT) for metastatic prostate cancer that has not been treated (or has been minimally treated) with testosterone-lowering agents. Methods Standard therapy for newly diagnosed metastatic prostate cancer has been ADT alone. Three studies have compared ADT alone with ADT and docetaxel, and two studies have compared ADT alone with ADT and abiraterone. Results Three prospective randomized studies (GETUG-AFU 15, STAMPEDE

EvidenceUpdates2018

53. Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer.

Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer. 29561693 2018 06 16 1527-7755 36 18 2018 Jun 20 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer. 1823-1830 10.1200 (...) /JCO.2017.75.5371 Purpose To compare the toxicities and cost of proton radiation and stereotactic body radiotherapy (SBRT) with intensity-modulated radiotherapy (IMRT) for prostate cancer among men younger than 65 years of age with private insurance. Methods Using the MarketScan Commercial Claims and Encounters database, we identified men who received radiation for prostate cancer between 2008 and 2015. Patients undergoing proton therapy and SBRT were propensity score-matched to IMRT patients

EvidenceUpdates2018

54. Primary cryotherapy for localised or locally advanced prostate cancer.

Primary cryotherapy for localised or locally advanced prostate cancer. BACKGROUND: Traditionally, radical prostatectomy and radiotherapy with or without androgen deprivation therapy have been the main treatment options to attempt to cure men with localised or locally advanced prostate cancer. Cryotherapy is an alternative option for treatment of prostate cancer that involves freezing of the whole prostate (whole gland therapy) or only the cancer (focal therapy), but it is unclear how effective (...) this is in comparison to other treatments. OBJECTIVES: To assess the effects of cryotherapy (whole gland or focal) compared with other interventions for primary treatment of clinically localised (cT1-T2) or locally-advanced (cT3) non-metastatic prostate cancer. SEARCH METHODS: We updated a previously published Cochrane Review by performing a comprehensive search of multiple databases (CENTRAL, MEDLINE, EMBASE), clinical trial registries (ClinicalTrials.gov, World Health Organization International Clinical Trials

Cochrane2018

55. Cancer Treatment–Induced Bone Loss in Women With Breast Cancer and Men With Prostate Cancer

Cancer Treatment–Induced Bone Loss in Women With Breast Cancer and Men With Prostate Cancer 29942922 2018 11 14 2472-1972 2 7 2018 Jul 01 Journal of the Endocrine Society J Endocr Soc Cancer Treatment-Induced Bone Loss in Women With Breast Cancer and Men With Prostate Cancer. 574-588 10.1210/js.2018-00052 Cancer and cancer therapies can have a negative impact on bone health. Because cancer is a common diagnosis, survivorship concerns for osteoporosis and fragility fractures are an important (...) component of care. This review addresses management of bone health in nonmetastatic cancer survivorship with a focus on breast cancer and prostate cancer. Taxel Pamela P UConn Health Center, Farmington, Connecticut. Faircloth Erika E UConn Health Center, Farmington, Connecticut. Idrees Sana S Saint Vincent's Hospital, Bridgeport, Connecticut. Van Poznak Catherine C University of Michigan Health Center, Ann Arbor, Michigan. eng Journal Article Review 2018 05 21 United States J Endocr Soc 101697997 2472

Journal of the Endocrine Society2018 Full Text: Link to full Text with Trip Pro

56. Survivin polymorphisms and susceptibility to prostate cancer: A genetic association study and an in silico analysis

Survivin polymorphisms and susceptibility to prostate cancer: A genetic association study and an in silico analysis 30034311 2018 11 14 1611-2156 17 2018 EXCLI journal EXCLI J Survivin polymorphisms and susceptibility to prostate cancer: A genetic association study and an in silico analysis. 479-491 10.17179/excli2018-1234 Survivin is a member of the apoptosis inhibitor protein family and its polymorphisms may lead to susceptibility to cancer. The aim of this study was to investigate (...) the possible association of c.-31G>C (rs9904341), c.454G>A (rs2071214), c.*148T>C (rs2239680) and c.*571T>C (rs1042489) polymorphisms of survivin gene with prostate cancer risk and provide some justification using in silico analysis. The 157 men with prostate cancer and 145 healthy controls were included in a case-control study. The studied polymorphisms were genotyped using PCR-RFLP method. An in silico approach was employed to show the possible effects of the polymorphisms on the survivin gene function

EXCLI journal2018 Full Text: Link to full Text with Trip Pro

57. Development of sarcosine quantification in urine based on enzyme-coupled colorimetric method for prostate cancer diagnosis

Development of sarcosine quantification in urine based on enzyme-coupled colorimetric method for prostate cancer diagnosis 30034310 2018 11 14 1611-2156 17 2018 EXCLI journal EXCLI J Development of sarcosine quantification in urine based on enzyme-coupled colorimetric method for prostate cancer diagnosis. 467-478 10.17179/excli2018-145 An enzyme-coupled colorimetric assay for quantification of urinary sarcosine was developed. The proposed method is a specific reaction based on hydrogen peroxide (...) , respectively. A good linearity was revealed with a coefficient of 0.990. The assay showed no significant interference from ascorbic acid, glucose and bilirubin. In addition, it is extremely specific for sarcosine rather than other amino acids. The determination of sarcosine in human urine displayed high accuracy and good reproducibility. This method is promising to differentiate prostate cancer patients from healthy subjects according to urinary sarcosine level. Altogether, this study provides a rapid

EXCLI journal2018 Full Text: Link to full Text with Trip Pro

58. Use of Conservative Management for Low-Risk Prostate Cancer in the Veterans Affairs Integrated Health Care System From 2005-2015

Use of Conservative Management for Low-Risk Prostate Cancer in the Veterans Affairs Integrated Health Care System From 2005-2015 29800017 2018 07 10 2018 12 02 1538-3598 319 21 2018 06 05 JAMA JAMA Use of Conservative Management for Low-Risk Prostate Cancer in the Veterans Affairs Integrated Health Care System From 2005-2015. 2231-2233 10.1001/jama.2018.5616 Loeb Stacy S Manhattan Veterans Affairs Medical Center, New York, New York. Byrne Nataliya N Department of Urology, New York University (...) Conservative Treatment statistics & numerical data trends Delivery of Health Care, Integrated Humans Logistic Models Male Middle Aged Multivariate Analysis Prostate-Specific Antigen blood Prostatic Neoplasms therapy Risk Factors United States United States Department of Veterans Affairs Veterans Watchful Waiting 2018 5 26 6 0 2018 7 11 6 0 2018 5 26 6 0 ppublish 29800017 2681802 10.1001/jama.2018.5616 PMC6134433 JAMA Oncol. 2017 Oct 1;3(10):1393-1398 27768168 BJU Int. 2017 Jul;120(1):32-39 27611479 J Clin

JAMA2018 Full Text: Link to full Text with Trip Pro

59. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.

Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. Importance: In the United States, the lifetime risk of being diagnosed with prostate cancer is approximately 13%, and the lifetime risk of dying of prostate cancer is 2.5%. The median age of death from prostate cancer is 80 years. Many men with prostate cancer never experience symptoms and, without screening, would never know they have the disease. African American men and men with a family history (...) of prostate cancer have an increased risk of prostate cancer compared with other men. Objective: To update the 2012 US Preventive Services Task Force (USPSTF) recommendation on prostate-specific antigen (PSA)-based screening for prostate cancer. Evidence Review: The USPSTF reviewed the evidence on the benefits and harms of PSA-based screening for prostate cancer and subsequent treatment of screen-detected prostate cancer. The USPSTF also commissioned a review of existing decision analysis models

JAMA2018

60. Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.

Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force. Importance: Prostate cancer is the second leading cause of cancer death among US men. Objective: To systematically review evidence on prostate-specific antigen (PSA)-based prostate cancer screening, treatments for localized prostate cancer, and prebiopsy risk calculators to inform the US Preventive Services Task Force. Data Sources: Searches of PubMed (...) Extraction and Synthesis: One investigator abstracted data; a second checked accuracy. Two investigators independently rated study quality. Main Outcomes and Measures: Prostate cancer and all-cause mortality; false-positive screening results, biopsy complications, overdiagnosis; adverse effects of active treatments. Random-effects meta-analyses were conducted for treatment harms. Results: Sixty-three studies in 104 publications were included (N = 1 904 950). Randomization to PSA screening was

JAMA2018